背景:尽管有几项研究报道了雌激素治疗对跨性别和非二元(TGNB)个体的面部和体毛的抑制作用,很少有研究阐明其对头皮发际线稳定性的影响。在这项研究中,我们评估了雌激素治疗对额头长度的影响.
方法:所有TGNB患者,30岁或以上,本研究纳入了寻求面部女性化手术的出生时分配男性(AMAB).在最初的咨询访问中收集了中央和前额的长度。变量,包括年龄,激素替代疗法(HRT)的持续时间,螺内酯的存在,以及其他头发护理的存在,如非那雄胺,dutasteride,或者米诺地尔,通过图表审查收集了可能影响头发生长的因素。使用相关的预测变量构建多变量线性回归,同时还纳入全球健康评分作为对脱发的心理影响的代理。
结果:总体而言,这项研究包括171名患者,年龄中位数为36.0(四分位距(IQR)32.0-46.0)岁,HRT持续时间中位数为2.0(IQR1.0-6.0)年。多变量线性回归显示中央前额长度没有显著预测因子。然而,前额外侧长度按年龄呈正预测(B=0.06,95%置信区间(CI)[0.03-0.08],p<0.001)和头发处理(B=0.66,95%CI[0.14-1.18],p=0.01),但由HRT持续时间负预测(B=-0.07,95%CI[-0.10至-0.04],p<0.001)。
结论:尽管年龄较大是TGNBAMAB个体发际线横向衰退的预测因素,在30岁以上的患者中,随着女性激素治疗的每年,前额外侧长度也会减少0.07cm。
BACKGROUND: Although several studies report on the suppressing effects of estrogen therapy on facial and body hair in transgender and nonbinary (TGNB) individuals, few studies have elucidated its effects on hairline stability on the scalp. In this study, we assessed the influence of estrogen therapy on forehead length.
METHODS: All TGNB patients, aged 30 years or older, assigned male at birth (AMAB) seeking facial feminization surgery were included in the study. Central and forehead lengths were collected at the initial consultation visits. Variables, including age, duration of hormone replacement therapy (HRT), presence of spironolactone, and presence of other hair treatments, such as finasteride, dutasteride, or minoxidil, that potentially influence hair growth were collected by chart review. Multivariable linear regressions were constructed with relevant predictor variables while also incorporating global health scores as a proxy for psychological effects on hair loss.
RESULTS: Overall, 171 patients were included in this study, with a median age of 36.0 (interquartile range (IQR) 32.0-46.0) years and median HRT duration of 2.0 (IQR 1.0-6.0) years. Multivariable linear regressions revealed no significant predictors for central forehead length. However, lateral forehead length was positively predicted by age (B=0.06, 95% confidence interval (CI) [0.03-0.08], p < 0.001) and hair treatment (B=0.66, 95% CI [0.14-1.18], p = 0.01), but negatively predicted by HRT duration (B=-0.07, 95% CI [-0.10 to -0.04], p < 0.001).
CONCLUSIONS: Although older age is a predictor of lateral hairline recession in TGNB AMAB individuals, lateral forehead length was also predicted to decrease by 0.07 cm with each year of feminizing hormone therapy in patients over 30 years of age.